TICKERNERD
Menu
ONCYONCYHealthcare · Biotechnology

ONCY Stock Forecast: Oncolytics Biotech, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$0.47
−15.48% on the day

The 6 Wall Street analysts covering Oncolytics Biotech, Inc. hold a median 12-month price target of $4.14 — +775.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 12 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$73.0M
Ticker Nerd rank
36 / 100
Median analyst target
$4.14
Analysts covering
6
Revenue$0.0
Operating income−$9.4M
Net income−$9.4M
Free cash flow−$8.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−21.1%
1M
−36.9%
YTD
−45.6%
1Y
−60.6%
From 52W high
−62.7%
From 52W low
0.0%
$0.47
$1.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ONCY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Oncolytics Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Size
79
Issuance
56
Value
48
Volatility
47
Revisions
44
Growth
30
Momentum
16
Quality
12

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ONCY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ONCY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26ONCYHigh $5.85Median $4.14Low $2.84

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $2.84Median $4.14High $5.85

The green dot is the last close — the median target sits +775.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Aug 2026HC Wainwright & Co.MaintainsBuy$10 → $5.00
26 May 2026HC Wainwright & Co.ReiteratesBuy—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
13 Aug 2025Lake StreetInitiatesBuy—
21 May 2025HC Wainwright & Co.ReiteratesBuy—
16 May 2025Jones TradingDowngradeHold—
10 Mar 2025HC Wainwright & Co.ReiteratesBuy—
10 Mar 2025Maxim GroupMaintainsBuy—
10 Mar 2025RBC CapitalMaintainsOutperform—
3 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
19 Sept 2024HC Wainwright & Co.ReiteratesBuy—
21 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024Raymond JamesInitiatesOutperform—
8 Mar 2024HC Wainwright & Co.MaintainsBuy—
14 Feb 2024HC Wainwright & Co.ReiteratesBuy—
19 Jan 2024HC Wainwright & Co.ReiteratesBuy—
4 Jan 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ONCY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ONCY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Oncolytics Biotech, Inc. returned −60.6% against +20.4% for the S&P 500, dividends included.

ONCY vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ONCYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ONCY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Oncolytics Biotech, Inc. (ONCY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
−10.8×

Cheaper than 98% of US stocks

EV / EBITDA
−1.8×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
757.0%

Higher than 99% of US stocks

Return on assets
−211.2%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Oncolytics Biotech, Inc. (ONCY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oncolytics Biotech, Inc. has a market value of $73.0M and an enterprise value of $67.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$38.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$26.7M.

  • Shares outstanding: 116.1M.

  • Trailing P/E: −1.9×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%.

  • Oncolytics Biotech, Inc. employs 29 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Oct 2026

Data provided by Twelve Data

Peers

ONCY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ONCYOncolytics Biotech, Inc.$73.0M
36
XLOXilio Therapeutics, Inc.$59.7M
74
PLRXPliant Therapeutics, Inc.$61.0M
69
APLMApollomics, Inc.$62.1M
20
GUTSFractyl Health, Inc.$58.5M
30
LONALeonaBio, Inc.$57.3M
42
BOLDBoundless Bio, Inc.$57.1M
82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Oncolytics Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ONCY news & analysis

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

GlobeNewsWire · 12 Oct 2026positive

Oncolytics Biotech reported that a new patent covering pelareorep’s use as a cancer immunotherapy has been issued in several countries, with U.S. issuance expected soon. The company also outlined three pending patent applications and plans to pursue composition-of-matter protection for a modified, next-generation pelareorep, aiming to extend protection into the late 2040s, subject to issuance and applicable terms.

Why it matters — The update describes the company’s efforts to broaden and extend intellectual property protection for pelareorep and future versions of the therapy.

FAQ

Frequently asked questions about ONCY stock

What is the ONCY stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Oncolytics Biotech, Inc. have a median 12-month price target of $4.14, with estimates ranging from $2.84 to $5.85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ONCY stock a buy right now?

Of the 6 analysts covering Oncolytics Biotech, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oncolytics Biotech, Inc. 36 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ONCY?

As at 12 Oct 2026, Oncolytics Biotech, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will ONCY stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +775.3% from the last close, and Ticker Nerd's factor model ranks Oncolytics Biotech, Inc. 36 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ONCY stock forecast for 2030?

No analyst covering Oncolytics Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ONCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.84 to $5.85 over the next 12 months.

How has ONCY stock performed over the past year?

Oncolytics Biotech, Inc. returned -60.6% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oncolytics Biotech, Inc. do?

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent designed to stimulate the innate and adaptive immune systems against cancer.

What is the latest news on ONCY?

The most recent item we track (GlobeNewsWire, 12 Oct 2026): "Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update". Oncolytics Biotech reported that a new patent covering pelareorep’s use as a cancer immunotherapy has been issued in several countries, with U.S. issuance expected soon. The company also outlined three pending patent applications and plans to pursue composition-of-matter protection for a modified, next-generation pelareorep, aiming to extend protection into the late 2040s, subject to issuance and applicable terms.

Company

About Oncolytics Biotech, Inc.

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent designed to stimulate the innate and adaptive immune systems against cancer. The company’s current programs center on solid tumors and hematological malignancies, with particular emphasis on gastrointestinal cancers such as colorectal, pancreatic, and anal cancers, as well as hormone receptor-positive, HER2-negative breast cancer. Its research approach combines pelareorep with chemotherapy and immune checkpoint inhibitors to improve how tumors respond to treatment. Oncolytics Biotech also advances clinical studies and regulatory development efforts through its pipeline and strategic collaborations, positioning the company within the oncology immunotherapy market.

CEO Mr. Jared Kelly J.D., L.L.M. · 29 employees · United States · https://oncolyticsbiotech.com